Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
Monoclonal antibodies (mAbs) radiolabeled by use of metal chelators are being investigated in the laboratory for use in clinical trials. 111In is presently employed for diagnostic scintigraphy, but its applications are limited by substantive and persistant uptake of radiometal in the liver. Much current research is focused on performing cancer therapy with 90Y and 212Bi chelate-linked mAbs. This report chronicles the development and evaluation of chelating agents for 111In-radioimmunoimaging and 90Y- and 212Bi-radioimmunotherapy.
Gansow
O A
OA
Chemistry Section, Radiation Oncology Branch, National Institutes of Health, Bethesda, MD 20892.
D000911:Antibodies, Monoclonal / Q000737:chemistry*; D001729:Bismuth / Q000737:chemistry / Q000627:therapeutic use; D002614:Chelating Agents / Q000737:chemistry*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007205:Indium Radioisotopes / Q000737:chemistry; D007553:Isotope Labeling / Q000379:methods*; D008024:Ligands; D015394:Molecular Structure; D011868:Radioisotopes / Q000737:chemistry* / Q000627:therapeutic use; D011877:Radionuclide Imaging / Q000379:methods; D011878:Radiotherapy / Q000379:methods; D015021:Yttrium Radioisotopes / Q000737:chemistry / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D002614:Chelating Agents; D007205:Indium Radioisotopes; D008024:Ligands; D011868:Radioisotopes; D015021:Yttrium Radioisotopes; D001729:Bismuth